2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Orexin Receptor (OX Receptor)
  5. Orexin Receptor (OX Receptor) Agonist

Orexin Receptor (OX Receptor) Agonist

Orexin Receptor (OX Receptor) Isoform Comparison

Orexin Receptor (OX Receptor) Agonists (40):

Cat. No. Product Name Effect Purity
  • HY-106224
    Orexin A (human, rat, mouse)
    		Agonist 99.93%
    Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)), a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats.
  • HY-106224B
    Orexin A (human, rat, mouse) acetate
    		Agonist 99.67%
    Orexin A (Hypocretin-1) (human, rat, mouse) acetate is a hypothalamic neuropeptide with analgesic properties (crosses the blood-brain barrier). Orexin A (human, rat, mouse) acetate binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) acetate can be used in studies of appetite regulation, neurodegenerative diseases and modulation of injurious messaging.
  • HY-P1339A
    Orexin B, human TFA
    		Agonist 99.46%
    Orexin B, human (TFA) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
  • HY-159835
    Oveporexton
    		Agonist 99.68%
    Oveporexton (TAK-861) is an orally active and selective orexin receptor 2 (OX2R) agonist with an EC50 of 2.5 nM. Oveporexton exhibits 3000-fold selectivity for OX2R over OX1R. Oveporexton can be used for the study of hypersomnia disorders including narcolepsy.
  • HY-P1339B
    Orexin B, human acetate
    		Agonist 99.68%
    Orexin B, human acetate is the acetate form of Orexin B, human (HY-P1339). Orexin B, human acetate is the agonist for Orexin Receptor, with Ki of 420 nM and 36 nM for OX1 and OX2. Orexin B, human acetate participates in the regulation of appetite, wakefulness, cardiovascular function and neuroendocrine.
  • HY-19320
    Orexin 2 Receptor Agonist
    		Agonist 99.59%
    Orexin 2 Receptor Agonist is a potent selective OX2R agonist with an EC50 of 23 nM.
  • HY-106224A
    Orexin A (human, rat, mouse) TFA
    		Agonist 98.13%
    Orexin A (human, rat, mouse) (Hypocretin-1 (human, rat, mouse)) TFA, a 33 amino acid excitatory neuropeptide, orchestrates diverse central and peripheral processes. Orexin A (human, rat, mouse) TFA binds and activates two types of G protein-coupled receptors, the orexin-1 receptor (OX1R) and the orexin-2 receptor (OX2R). Orexin A (human, rat, mouse) TFA has a role in the regulation of feeding behavior. Orexin A (human, rat, mouse) TFA is an effective anti-nociceptive and anti-hyperalgesic agent in mice and rats.
  • HY-154789
    RTIOXA-43
    		Agonist 99.94%
    RTIOXA-43 is a orexin receptor agonist with EC50s of 24 nM and 24 nM for OX2 and OX1 receptors, respectively.
  • HY-P99249
    Vonlerolizumab
    		Agonist 99.70%
    Vonlerolizumab (Pogalizumab; MOXR 0916) is a humanized IgG1 monoclonal antibody targeting OX40 (CD134). Pogalizumab partially blocks the interaction between OX40 and its natural ligand OX40L upon binding, thereby activating the NF-κB signaling pathway. Pogalizumab enhances T cell activation and proliferation and has shown antitumor activity in mouse models.
  • HY-136181A
    YNT-185
    		Agonist 98.46%
    YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models.
  • HY-172412
    Alixorexton
    		Agonist 99.96%
    Alixorexton (ALKS 2680) is an orally bioavailable, blood-brain barrier-permeable OX2R-selective activator and wake-promoting agent. Alixorexton can be used for the research of narcolepsy and idiopathic hypersomnia.
  • HY-P1341
    OXA(17-33)
    		Agonist
    OXA (17-33) (Orexin A (17-33) (human, mouse, rat, bovine)) is the shortest active orexin peptide that selectively targets OX1 (EC50=8.29 nM), with 23-fold selectivity for the OX1 receptor over the OX2 receptor. The activity of OXA (17-33) depends on the Tyr17, Leu20, Asn25, His26 residues and the spatial conformation of the α-helix. OXA (17-33) activates signaling pathways involving inositol-1,4,5-trisphosphate receptor (IP3R), phospholipase D (PL-D) and choline-Sigma-1R, thereby increasing the cytoplasmic Ca2+ level in nucleus accumbens neurons, an effect that is blocked by Sigma-1R antagonists. OXA (17-33) serves as an important biological probe for investigating the function of the OX1 receptor. OXA (17-33) can be modified via incorporation of mixed disulfide bonds of homocysteine and cysteamine, and is widely used in studies related to insomnia and narcolepsy.
  • HY-137440
    Firazorexton
    		Agonist 99.56%
    Firazorexton (TAK-994 free base) is an orally active and brain-penetrant orexin type 2 receptor (OX2R) selective agonist. Firazorexton (TAK-994 free base) can promote wakefulness and has the potential to improve narcolepsy-like symptoms in mice.
  • HY-171032
    (R)-YNT-3708
    		Agonist 99.07%
    (R)-YNT-3708 is a selective orexin 1 (OX1R) agonist, with an EC50 of 7.48 nM. (R)-YNT-3708 has antinociceptive effects.
  • HY-P1349
    Orexin B, rat, mouse
    		Agonist 99.66%
    Orexin B, rat, mouse (Rat orexin B) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
  • HY-P991336
    Ordastobart
    		Agonist 98%
    Ordastobart (INBRX-106; ES-102) is a hexavalent OX40 agonist antibody. Ordastobart enhances OX40 receptor clustering, signaling, and downstream activation, thereby increasing the proliferation and activation of CD4+ and CD8+ T cells in vitro and in vivo. Ordastobart exhibits anti-tumor effects and improves survival in mouse models of cancer. Ordastobart is indicated for research in cancers such as fibrosarcoma and colorectal cancer.
  • HY-136181
    YNT-185 dihydrochloride
    		Agonist 99.78%
    YNT-185 dihydrochloride is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 dihydrochloride ameliorates narcolepsy-cataplexy symptoms in mouse models.
  • HY-P1349A
    Orexin B, rat, mouse TFA
    		Agonist 98.68%
    Orexin B, rat, mouse (Rat orexin B) TFA is an endogenous orexin receptor agonist. Orexin B, rat, mouse TFA binds and activates two closely related orphan G protein-coupled receptors OX1-R and OX2-R. Orexin B, rat, mouse TFA stimulates food intake and energy expenditure and plays a significant role in sleep-wakefulness regulation.
  • HY-137452
    Suntinorexton
    		Agonist 98.66%
    Suntinorexton is an OX2R agonist. Suntinorexton is used to study respiratory function during sleep.
  • HY-P1340
    [Ala11,D-Leu15]-Orexin B(human)
    		Agonist 98.31%
    [Ala11,D-Leu15]-Orexin B(human) is a potent and selective orexin-2 receptor (OX2) agonist. [Ala11,D-Leu15]-Orexin B(human) shows a 400-fold selectivity for the OX2 (EC50=0.13 nM) over OX1 (52 nM).